Zachary Lee, DO
Internal Medicine · Jonesboro, ARNPI 1497376040
Payments from drug & device makers
Across 250 payments — averaging $17.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$681
- GSK$508
- Amgen$419
- Sumitomo Pharma America, Inc.$289
- Astellas Pharma US Inc$284
- Otsuka America Pharmaceutical, Inc.$270
- plus $2K from 31 others
What the payments were for
- Food & beverage$4,350100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 34 | $681 |
| GSK | 35 | $508 |
| Amgen | 33 | $419 |
| Sumitomo Pharma America, Inc. | 17 | $289 |
| Astellas Pharma US Inc | 14 | $284 |
| Otsuka America Pharmaceutical, Inc. | 11 | $270 |
| AbbVie | 16 | $252 |
| Pfizer | 11 | $185 |
| Boehringer Ingelheim | 8 | $149 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $133 |
| Novo Nordisk | 7 | $121 |
| Lilly USA, LLC | 7 | $111 |
| Novartis | 5 | $99 |
| Daiichi Sankyo Inc. | 4 | $91 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $68 |
| Phathom Pharmaceuticals, Inc. | 6 | $64 |
| Edwards Lifesciences | 2 | $56 |
| Esperion Therapeutics, Inc. | 3 | $54 |
| Lundbeck LLC | 3 | $53 |
| Averitas Pharma Inc. | 2 | $43 |
| Sanofi-aventis U.S. LLC | 1 | $39 |
| Ardelyx, Inc. | 2 | $39 |
| Medtronic | 2 | $37 |
| Bayer | 2 | $36 |
| Exact Sciences | 2 | $31 |
| Inspire Medical Systems, Inc. | 1 | $29 |
| Vertex | 1 | $28 |
| Scilex Pharmaceuticals Inc. | 1 | $22 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| Inogen, Inc. | 1 | $20 |
| Irhythm Technologies, Inc. | 1 | $19 |
| Cvrx, Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Aimmune Therapeutics, Inc. | 1 | $17 |
| Dexcom, Inc. | 1 | $16 |
| Merck | 1 | $15 |
| Evoke Pharma, Inc. | 1 | $15 |
How this compares
$4,350 in reported general payments places this provider in the 85th percentile of 614 internal medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 72 | $64,016 |
| EliquisApixaban | 81 | $63,814 |
| OzempicSemaglutide | 59 | $56,386 |
| MounjaroTirzepatide | 43 | $53,335 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $33,347 |
| RexultiBrexpiprazole | 12 | $17,787 |
| LinzessLinaclotide | 18 | $15,336 |
| EntrestoSacubitril/Valsartan | 14 | $10,513 |
| FarxigaDapagliflozin Propanediol | 16 | $9,939 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $9,848 |
| OxycontinOxycodone Hcl | 42 | $9,642 |
| GemtesaVibegron | 15 | $7,342 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 116 | $3,297 |
| Atorvastatin Calcium | 278 | $2,673 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 181 | $2,673 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $149 | $64,01672 claims |
| PfizerEliquis | $185 | $63,81481 claims |
| Novo NordiskOzempic | $121 | $56,38659 claims |
| Lilly USA, LLCMounjaro | $111 | $53,33543 claims |
| GSKTrelegy Ellipta | $508 | $33,34741 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $681 | $19,78733 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $270 | $17,78712 claims |
| AbbVieLinzess, Synthroid | $252 | $16,37836 claims |
| NovartisEntresto | $99 | $10,51314 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $289 | $7,34215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 614 internal medicine providers in Arkansas.
Other internal medicine in Jonesboro
- David PyleJonesboro$93K
- John NorwoodJonesboro$22K
- Revel PorterJonesboro$12K
- Ricky TateJonesboro$11K
- Brannon TreeceJonesboro$9K
- Veryl HodgesJonesboro$8K
- Corey DiamondJonesboro$8K
- Veronica EastonJonesboro$5K
- Priyantha WijewardaneLittle Rock$43.6M
- Joseph RoseLittle Rock$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.